arrow
M

Min Kyong Moon

seoul national university
H指数:39
被引数:5,219

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

β‐Cell Recovery Patterns With Initial Combination Versus Stepwise Therapy in Newly Diagnosed Type 2 Diabetes: TRIPLE ‐ AXEL Post Hoc Analysis

新诊断2型糖尿病中初始联合治疗与逐步治疗后的β细胞恢复模式:<scp>TRIPLE</scp>‐<scp>AXEL</scp>事后分析

2026-11-030
PRE
Ethylparaben and consumer chemicals and their associations with metabolic disorders: A multicycle analysis of Korean National Environmental Health Survey (2015–2020)

对乙酰氨基酚和对羟基苯甲酸乙酯及消费者化学品与其与代谢紊乱的关联:一项韩国国家环境健康调查(2015–2020)的多周期分析

2025-12-100
PRE
Efficacy and safety of switching to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus and dyslipidaemia: A multicentre, prospective study (EROICA study)

韩国2型糖尿病合并血脂异常患者转换为依折麦布10 mg/罗苏伐他汀2.5 mg的疗效与安全性:一项多中心、前瞻性研究(EROICA研究)

2025-11-050
OAAI
Bridging Evidence and Practice: A Consensus Statement from the Korean Diabetes Association on Diabetes Screening, Pharmacological Treatment and Severe Diabetes
2025-11-010
OA
EffiCacy and safety of ANagliptin when added to iNsulin and metformin therapy in patients with uncontrolled type 2 diAbetes; randomized, placebo-controlled, double-blind, multicentre trial (CANNA study)

埃格利汀(ANagliptin)在胰岛素和二甲双胍疗法基础上添加治疗未控制2型糖尿病的疗效与安全性;随机、安慰剂对照、双盲、多中心试验(CANNA研究)

2025-06-250
OA
The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension

胰高血糖素样肽-1受体激动剂(GLP1-RAs)在代谢综合征合并高血压患者管理中的作用:韩国高血压学会立场文件

2024-09-010
OAAI
2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association
2024-07-314
OAAI
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association

韩国糖尿病协会糖尿病2023临床实践指南

2023-09-3038
OAAI